Assertio Therapeutics

ASRT69

High Growth

$0.94arrow_drop_down3.28%-$0.03

High Growth

Penny Stock

ASRT69

$0.94

arrow_drop_down3.28%-$0.03

High Growth

Penny Stock

Performance History

Key Stats
Open	$0.94
Prev. Close	$0.96
EPS	-4.94
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$89.82M
PE Ratio	-

	LOW	HIGH
Day Range	0.93	0.99
52 Week Range	0.73	2.60

Ratios

Revenue	-





EPS	-4.94

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Assertio Therapeutics (ASRT)

Assertio Therapeutics Inc, formerly known as Depomed Inc, is a specialty pharmaceutical company that focuses on developing and commercializing products to treat patients suffering from central nervous system (CNS) disorders. The company's portfolio includes both branded and generic products. Assertio's branded product portfolio consists of prescription pain medications, such as Gralise, which is an extended-release version of gabapentin, and Zipsor, which is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of mild to moderate acute pain. Its generic product portfolio includes products such as metformin extended-release tablets, which are used to manage type 2 diabetes, and glipizide extended-release tablets, which are used to control blood sugar levels in patients with type 2 diabetes.

In terms of its stock price history, Assertio Therapeutics Inc (ASRT) has experienced fluctuations over the years. In recent times, the stock price has been relatively low, but it is important to note that stock prices can be influenced by various factors, including market conditions, industry trends, and company performance. Investors should carefully consider these factors before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Daniel A. Peisert
Headquarters: Lake Forest
Employees: 30
Exchange: NASDAQ

Keep an eye on Assertio Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Assertio Therapeutics 's (ASRT) price per share?

The current price per share for Assertio Therapeutics (ASRT) is $0.94. The stock has seen a price change of -$0.03 recently, indicating a -3.28% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Assertio Therapeutics (ASRT)?

For Assertio Therapeutics (ASRT), the 52-week high is $2.6, which is 176.36% from the current price. The 52-week low is $0.73, the current price is 28.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Assertio Therapeutics (ASRT) a growth stock?

Assertio Therapeutics (ASRT) has shown an average price growth of -4.13% over the past three years. It has received a score of 73 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Assertio Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Assertio Therapeutics (ASRT) stock price performance year to date (YTD)?

As of the latest data, Assertio Therapeutics (ASRT) has a year-to-date price change of -17.47%. Over the past month, the stock has experienced a price change of -16%. Over the last three months, the change has been -24.13%. Over the past six months, the figure is -9.54%. Looking at a longer horizon, the five-year price change stands at -68.1%.

help

Is Assertio Therapeutics (ASRT) a profitable company?

Assertio Therapeutics (ASRT) has a net income of -$331.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 82.23% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -9.41% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $125.05M. Operating income is noted at -$243.54M. Furthermore, the EBITDA is $36.68M.

help

What is the market capitalization of Assertio Therapeutics (ASRT)?

Assertio Therapeutics (ASRT) has a market capitalization of $89.83M. The average daily trading volume is 0.96, indicating the stock's liquidity and investor engagement.